Dr. Aaron P. Varghese, MD

Dr. Varghese practices at Smh Infusion Center at Highland Hos - Outpatient Oncology at Hh - HOPD in Rochester, New York.

Dr. Varghese's NPI, 1518384668, was assigned on March 26, 2014. Dr. Varghese holds New York license 324433.

Dr. Varghese's primary practice is Smh Infusion Center at Highland Hos - Outpatient Oncology at Hh - HOPD, at 1000 South Ave, Rochester, NY 14620.

Dr. Varghese's primary practice is Smh Infusion Center at Highland Hos - Outpatient Oncology at Hh - HOPD in Rochester, New York. Dr. Varghese is also affiliated with Highland Hospital. The medical group on file is University of Rochester Medical Faculty Group (URMFG). Dmand AI also links Dr. Varghese to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Varghese practices, 7 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Varghese's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Varghese is licensed in New York.

CMS data shows 392 Medicare services from Dr. Varghese across 7 procedure codes in 2024, for 98 Medicare patients. Medicare paid $18,278 for them.

CMS counts 98 Medicare patients who saw Dr. Varghese in 2024. The largest group is 65 to 74, with 55 patients. 71% of them have high cholesterol, and 63% have high blood pressure. 15% are also on Medicaid. Their average risk score is 1.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Varghese's median patient age at 65, with 99% women.

In 2024, Dr. Varghese wrote 68 Medicare Part D claims for 26 patients. 90% of them were for generic drugs. CMS names the drug for 39 of them, across 2 drugs with 11 or more claims each, at $269 in total drug cost. In 2017, CMS named 12 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Varghese for performance year 2024, reported as part of a group. Dr. Varghese accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 27 procedures of removal of the uterus by Dr. Varghese, more than 96% of the clinicians it reports for that procedure.

Dmand AI links 10 papers to Dr. Varghese, published from 2017 to 2025. 2019 was the busiest year, with 2. The most frequent topics are Ovarian Neoplasms and Peritoneal Neoplasms. Dr. Varghese has published most often in Gynecol Oncol Rep. Dr. Varghese's most frequent co-authors are Emese Zsiros, MD, Cynthia L. Angel, MD and Javad Raymond Azadi, MD.

CMS Open Payments shows 1 general payment to Dr. Varghese from 1 drug or device company in 2017. Food and beverage make up the largest share, 100% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $11.